Plant Name: Diospyros kaki
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CHRM1; CHRM3; CHRM4; CHRM5; ADORA3; HTR2A; GPBAR1; DRD4; CHRM2; | |
| NPSR1; CXCR1; | |
| ALPI; PLA2G1B; TDP1; FAAH; RECQL; TERT; PIK3R1; GLO1; HPGD; MPO; AKR1B1; HSD17B10; HSD11B1; HSD17B2; ALOX15; AKR1B10; ALDH1A1; ALOX12; GFER; NOX4; PYGL; POLB; | |
| PTPRF; PTPN1; CDC25B; PTPN2; ACP1; | |
| ACHE; GAA; | |
| AKT1; MET; CSNK2A1; DAPK1; AXL; NEK2; FLT3; NEK6; CAMK2B; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; PIM1; NUAK1; ALK; KDR; PKN1; | |
| CA5B; CA3; CA14; CA7; CA9; CA4; CA6; CA2; CA12; CA1; CA5A; | |
| PPARA; PPARG; PPARD; | |
| NR1H4; | |
| RORC; | |
| KDM4E; | |
| MAOA; ALOX5; XDH; | |
| CASP7; CASP1; | |
| MMP13; MMP3; MMP2; MMP9; | |
| BACE1; | |
| TLR2; | |
| STAT6; HIF1A; NFKB1; TP53; | |
| FUT7; | |
| ABCC1; ABCG2; | |
| LMNA; FABP5; FABP2; FABP4; MAPT; FABP3; HTT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
| Small molecule receptor (family A GPCR) | CHRM4 | Muscarinic acetylcholine receptor M4 | P08173 | CHEMBL1821 |
| Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 4.977E-12 | 2.709E-09 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 4.977E-12 | 2.709E-09 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 2.973E-11 | 1.407E-08 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.021E-10 | 3.586E-08 | ALPI, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, GLO1, MMP13, MMP2, MMP3, MMP9, NR1H4, PPARA, PPARD, PPARG, PTPN1, RORC, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.481E-09 | 6.002E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.346E-09 | 1.188E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.745E-08 | 3.167E-06 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B, TLR2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.213E-08 | 3.794E-06 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.176E-08 | 6.687E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, MPO, NOX4, SRC |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.891E-07 | 2.481E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 3.643E-07 | 4.507E-05 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 4.384E-07 | 5.275E-05 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.772E-07 | 7.728E-05 | CYP1A2, CYP2C8, CYP3A4 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.136E-06 | 1.173E-04 | ADORA3, ALK, AXL, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CXCR1, DRD4, FLT3, GPBAR1, HPGD, HTR2A, IGF1R, KDR, MET, NPSR1, NR1H4, PPARA, PPARD, PPARG, PTPRF, RORC, TLR2 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.489E-06 | 1.480E-04 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.597E-06 | 1.574E-04 | ALOX12, ALOX15, ALOX5, HPGD |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.686E-06 | 1.646E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.910E-06 | 1.832E-04 | AKT1, HIF1A, LMNA, PPARD, SRC, TERT, TP53 |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 3.098E-06 | 2.721E-04 | AKT1, HIF1A, NOX4, NR1H4, PIK3R1, PPARG, PTPN2, PYGL |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 3.358E-06 | 2.902E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 3.746E-06 | 3.199E-04 | CYP19A1, NFKB1, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 4.080E-06 | 3.443E-04 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, NEK6, PKN1, SRC |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 4.921E-06 | 3.998E-04 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, PKN1 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.024E-06 | 4.039E-04 | AURKB, CA2, CA7, HIF1A, HTT, NEK2, NPSR1, NR1H4, PLA2G1B |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 5.140E-06 | 4.100E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.140E-06 | 4.100E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 5.425E-06 | 4.296E-04 | ACP1, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CASP1, CASP7, CDC25B, CDK1, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GFER, GLO1, GSK3B, HIF1A, HPGD, HTR2A, HTT, LMNA, MAPT, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PPARG, PTK2, PTPN1, PTPN2, PYGL, SRC, STAT6, TP53, XDH |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 6.256E-06 | 4.780E-04 | HPGD, MMP2, MMP9, TERT |
| BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 7.804E-06 | 5.722E-04 | NR1H4, PIK3R1, PTPN1, PTPN2, SRC |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 7.804E-06 | 5.722E-04 | NR1H4, PPARA, PPARD, PPARG, RORC |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 8.891E-06 | 6.347E-04 | ABCG2, ACHE, AKT1, ALK, CAMK2B, CASP1, CSNK2A1, DAPK1, DRD4, FLT3, HPGD, HTT, IGF1R, KDR, MAPT, MET, MMP9, NFKB1, PPARG, PYGL, STAT6, TERT, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.068E-05 | 7.429E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 1.330E-05 | 9.078E-04 | AKT1, CDK1, DAPK1, GSK3B, HIF1A, HTR2A, HTT, KDR, PPARA, PTK2, PTPN1 |
| BP | GO:0008152; metabolic process | GO:0071073; positive regulation of phospholipid biosynthetic process | 1.393E-05 | 9.423E-04 | FABP3, HTR2A, NR1H4 |
| MF | GO:0005488; binding | GO:0032052; bile acid binding | 1.393E-05 | 9.423E-04 | NR1H4, PLA2G1B, PYGL |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.401E-05 | 9.445E-04 | AURKB, CA2, CA7, HIF1A, HTR2A, HTT, KDR, NEK2, NPSR1, NR1H4, PLA2G1B, SRC |
| BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 1.706E-05 | 1.109E-03 | AKT1, FABP3, PPARA, PPARG |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.706E-05 | 1.109E-03 | AKT1, MAPT, PTPN1, TP53 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 1.864E-05 | 1.197E-03 | ADORA3, ALK, AXL, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CXCR1, DRD4, FLT3, GPBAR1, HPGD, HTR2A, IGF1R, KDR, MET, NPSR1, PPARG, PTPRF |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.960E-05 | 1.244E-03 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 1.982E-05 | 1.255E-03 | PPARG, SRC, TP53 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.213E-05 | 1.385E-03 | CA2, CA7, HTR2A, HTT, KDR, NPSR1, PLA2G1B, SRC |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.309E-05 | 1.428E-03 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 2.309E-05 | 1.428E-03 | AKR1B1, CYP19A1, CYP3A4, HSD11B1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 2.447E-05 | 1.508E-03 | AKT1, DAPK1, HTT, LMNA, SRC, TERT |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 2.715E-05 | 1.619E-03 | GSK3B, HTT, MAPT |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.761E-05 | 1.634E-03 | AKT1, CASP7, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4, PPARG, RORC, SRC |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.880E-05 | 1.695E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 2.920E-05 | 1.714E-03 | AKT1, CASP1, KDR, MAPT, SRC |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.946E-05 | 1.724E-03 | CSNK2A1, HIF1A, KDR, MAPT |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 3.040E-05 | 1.764E-03 | AKT1, ALOX15, AXL, CASP1, DAPK1, FABP4, FLT3, GSK3B, HIF1A, NFKB1 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.097E-05 | 1.770E-03 | ALOX12, ALOX15 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 3.104E-05 | 1.770E-03 | AXL, CSNK2A1, DRD4, GSK3B, PPARA, PPARG, RORC, SRC, TP53 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.097E-05 | 1.770E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.605E-05 | 1.997E-03 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.605E-05 | 1.997E-03 | CYP1A2, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 4.513E-05 | 2.438E-03 | GSK3B, HIF1A, HTT, NUAK1, TP53 |
| BP | GO:0009987; cellular process | GO:1900103; positive regulation of endoplasmic reticulum unfolded protein response | 4.667E-05 | 2.509E-03 | PIK3R1, PTPN1, PTPN2 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 5.171E-05 | 2.753E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 5.272E-05 | 2.792E-03 | ACHE, CASP1, HIF1A, NR1H4, PLA2G1B, PPARD, SRC, TLR2 |
| MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 5.295E-05 | 2.792E-03 | NEK6, PPARA, TERT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0071222; cellular response to lipopolysaccharide | 5.525E-05 | 2.885E-03 | AXL, CASP1, NFKB1, NR1H4, PPARD, SRC |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 5.527E-05 | 2.885E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 5.742E-05 | 2.977E-03 | NR1H4, PIM1, PPARA, PPARD, PPARG, RORC, SRC |
| BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 5.893E-05 | 3.038E-03 | AKT1, CASP1, CASP7, PTK2 |
| BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 5.901E-05 | 3.038E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
| CC | GO:0043226; organelle | GO:0043227; membrane-bounded organelle | 6.310E-05 | 3.218E-03 | ABCC1, ABCG2, ACHE, ACP1, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALK, ALOX12, AURKB, AXL, BACE1, CA1, CA2, CA4, CA5A, CA5B, CA6, CASP1, CASP7, CDK1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, FABP3, FABP4, FABP5, FLT3, FUT7, GAA, GFER, GLO1, GSK3B, HIF1A, HPGD, HSD17B10, HTR2A, HTT, IGF1R, KDM4E, KDR, LMNA, MAOA, MAPT, MMP2, MMP9, MPO, NEK6, NFKB1, NOX4, NUAK1, PIK3R1, PIM1, PKN1, PLA2G1B, POLB, PPARA, PPARD, PPARG, PTK2, PTPN1, PTPN2, PTPRF, PYGL, RECQL, RORC, SRC, TDP1, TERT, TLR2, TP53, XDH |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 6.418E-05 | 3.242E-03 | ADORA3, AKT1, ALK, CYP1B1, NFKB1, NR1H4, PIM1, PLA2G1B, PPARG, TLR2 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 6.708E-05 | 3.366E-03 | AXL, CDK1, CSNK2A1, FLT3, PPARG |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 8.670E-05 | 4.252E-03 | AKR1B1, AKT1, ALOX5, AURKB, CAMK2B, CASP7, CDC25B, CDK1, CSNK2A1, FABP5, GSK3B, HIF1A, HPGD, HTT, LMNA, NEK2, NEK6, NFKB1, NR1H4, NUAK1, PIM1, PKN1, POLB, PPARA, PPARD, PPARG, PTPN2, RECQL, RORC, SRC, STAT6, TERT, TP53 |
| BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 9.035E-05 | 4.391E-03 | AKT1, CDK1, PIK3R1, SRC, TERT, TLR2 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 9.035E-05 | 4.391E-03 | NR1H4, PPARA, PPARD, PPARG, RORC, SRC |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.258E-05 | 4.421E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 9.258E-05 | 4.421E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 9.258E-05 | 4.421E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 9.258E-05 | 4.421E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 9.258E-05 | 4.421E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 9.258E-05 | 4.421E-03 | GPBAR1, NR1H4 |
| BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 9.642E-05 | 4.528E-03 | AKT1, NR1H4, PIK3R1, TERT |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 9.648E-05 | 4.528E-03 | CASP1, CASP7, MAPT, PPARG, XDH |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.056E-04 | 4.935E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| BP | GO:0008152; metabolic process | GO:0046209; nitric oxide metabolic process | 1.092E-04 | 5.037E-03 | AKT1, CYP1B1, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 1.092E-04 | 5.037E-03 | CYP1A1, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.092E-04 | 5.037E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0050896; response to stimulus | GO:0009612; response to mechanical stimulus | 1.132E-04 | 5.190E-03 | AKT1, CASP1, HTR2A, MPO, NFKB1, PPARG, SRC |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.145E-04 | 5.236E-03 | ACHE, ALDH1A1, CHRM3, IGF1R, PIK3R1 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.154E-04 | 5.258E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.210E-04 | 5.466E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 1.245E-04 | 5.602E-03 | AKT1, ALOX12, AXL, CA2, CAMK2B, CDK1, CYP1B1, GSK3B, HIF1A, KDR, MAPT, NR1H4, PIK3R1, PIM1, PPARD, PPARG, PTK2, PTPN2, PTPRF, SRC, STAT6, TERT, TLR2, XDH |
| BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 1.305E-04 | 5.810E-03 | AKT1, HIF1A, TERT |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.370E-04 | 6.051E-03 | IGF1R, KDR, PTK2, SRC |
| MF | Unclassified; | GO:0032403; protein complex binding | 1.379E-04 | 6.079E-03 | ACHE, FLT3, HTR2A, IGF1R, KDR, MMP13, MMP9, PIK3R1, PPARA, PTPN1, PTPN2, PTPRF, SRC, TLR2 |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 1.500E-04 | 6.572E-03 | AKR1B10, ALDH1A1, CYP1A1, CYP1B1, PPARD |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.500E-04 | 6.572E-03 | AKT1, MAPT, NOX4, TP53, XDH |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 1.526E-04 | 6.668E-03 | ALK, CDK1, DRD4, PKN1, PLA2G1B, PTPN1 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 1.528E-04 | 6.668E-03 | ADORA3, CYP1B1, FABP3, LMNA, NOX4, PKN1, PPARD, PPARG, PTPN2, TERT, TLR2, TP53, XDH |
| BP | GO:0051179; localization | GO:0043269; regulation of ion transport | 1.532E-04 | 6.670E-03 | AKT1, CA2, CA7, CAMK2B, CHRM1, DAPK1, DRD4, HTR2A, HTT, MMP9, NPSR1, PLA2G1B |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.845E-04 | 7.800E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.845E-04 | 7.800E-03 | CYP1A1, CYP1A2 |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 1.934E-04 | 8.163E-03 | AKT1, HIF1A, MMP9, PTPN1, SRC |
| BP | GO:0008152; metabolic process | GO:0016311; dephosphorylation | 1.956E-04 | 8.238E-03 | ACP1, ALPI, CA3, CDC25B, POLB, PTPN1, PTPN2, PTPRF |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 2.064E-04 | 8.610E-03 | ABCG2, ACHE, AKT1, AXL, CAMK2B, FLT3, HIF1A, HPGD, MAPT, NFKB1, PIK3R1, PPARD, PPARG, PYGL, TERT, TLR2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.127E-04 | 8.788E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC |
| BP | GO:0051179; localization | GO:0015909; long-chain fatty acid transport | 2.192E-04 | 9.005E-03 | DRD4, FABP3, PLA2G1B, PPARG |
| BP | GO:0008152; metabolic process | GO:0019318; hexose metabolic process | 2.204E-04 | 9.037E-03 | AKR1B1, AKT1, ALDH1A1, FUT7, GAA, PPARD |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 2.237E-04 | 9.136E-03 | DRD4, PPARA, PPARG, RORC, TP53 |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 2.346E-04 | 9.498E-03 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
| BP | GO:0008152; metabolic process | GO:0005977; glycogen metabolic process | 2.357E-04 | 9.498E-03 | AKT1, GAA, GSK3B, PYGL |
| MF | GO:0005488; binding | GO:0043621; protein self-association | 2.357E-04 | 9.498E-03 | ACHE, FLT3, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 2.423E-04 | 9.715E-03 | HIF1A, TERT, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.325E-22 | 1.443E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.512E-16 | 1.091E-12 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.390E-15 | 5.975E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 8.124E-22 | 1.503E-19 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.299E-11 | 6.752E-09 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; MMP9; PTK2; IGF1R; KDR; AKT1; TP53; MET; TLR2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.676E-09 | 1.729E-07 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AKT1; PPARG; MET; TP53; PPARD |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 8.898E-09 | 3.292E-07 | CHRM2; CAMK2B; CHRM3; ACHE; CHRM1; CHRM4; CHRM5; AKT1; PIK3R1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.934E-08 | 1.040E-06 | CHRM2; GSK3B; CHRM1; PIK3R1; PTK2; NFKB1; IGF1R; KDR; AKT1; PKN1; TP53; MET; TLR2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.739E-09 | 1.729E-07 | HPGD; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.637E-08 | 8.130E-07 | HSD11B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.345E-07 | 2.720E-06 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; PPARA; NFKB1; PTPRF |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.470E-07 | 2.720E-06 | PTPN1; CSNK2A1; SRC; ACP1; MET; PTPRF; IGF1R |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 9.012E-08 | 2.084E-06 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.824E-07 | 4.749E-06 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.254E-07 | 8.900E-06 | FLT3; PIM1; AKT1; PIK3R1; NFKB1; PPARD |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.265E-06 | 1.672E-05 | SRC; AKT1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.502E-06 | 2.893E-05 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP3A4; CYP19A1; HSD17B10; HSD11B1; CYP2C8; FUT7; AKR1B10; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; ALPI; XDH |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.646E-06 | 2.030E-05 | FLT3; AKT1; PIK3R1; TP53; MET; HIF1A |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.708E-06 | 7.988E-05 | GSK3B; AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 7.634E-06 | 7.433E-05 | CAMK2B; GSK3B; SRC; AKT1; PIK3R1; PTK2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 9.067E-06 | 7.988E-05 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; TLR2 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.399E-05 | 1.125E-04 | GSK3B; SRC; KDR; AKT1; PIK3R1; MET; PTK2; IGF1R |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.194E-05 | 1.004E-04 | AKT1; PPARG; PIK3R1; TP53; NFKB1; IGF1R |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.480E-07 | 6.906E-06 | CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.410E-06 | 5.561E-05 | HSD11B1; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.685E-06 | 2.922E-05 | DAPK1; SRC; MMP2; MMP9; TP53 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 2.122E-05 | 1.454E-04 | CHRM2; CHRM3; CHRM1; SRC; CHRM4; CHRM5; PIK3R1; PTK2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.016E-05 | 1.454E-04 | CAMK2B; AKT1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.956E-05 | 1.454E-04 | SRC; KDR; AKT1; PIK3R1; PTK2 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.929E-05 | 1.806E-04 | CASP7; MMP3; AKT1; PIK3R1; MMP9; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.670E-05 | 1.703E-04 | CAMK2B; AKT1; PIK3R1; TP53; IGF1R |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.243E-05 | 1.935E-04 | CYP2C8; MAOA; ALOX5; ALOX15; ALOX12; HTR2A |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.119E-05 | 1.454E-04 | CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.352E-05 | 2.389E-04 | GSK3B; SRC; AKT1; PIK3R1; TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.782E-05 | 2.391E-04 | CAMK2B; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 4.102E-05 | 2.372E-04 | AKT1; PIK3R1; TP53; MET; IGF1R |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.670E-05 | 1.703E-04 | CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 7.027E-05 | 3.333E-04 | GSK3B; CXCR1; SRC; AKT1; PIK3R1; NFKB1; PTK2 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 4.782E-05 | 2.391E-04 | ABCC1; ADORA3; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.390E-05 | 2.389E-04 | GSK3B; SRC; AKT1; PIK3R1; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.037E-04 | 4.569E-04 | CHRM2; CAMK2B; CHRM1; AKT1; PIK3R1; PPARA; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 8.482E-05 | 3.923E-04 | GSK3B; AKT1; PIK3R1; PPARA; TP53; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.139E-04 | 4.681E-04 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.126E-04 | 4.681E-04 | CASP7; LMNA; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.303E-04 | 5.241E-04 | CHRM2; CHRM3; CHRM1; CHRM4; ADORA3; CHRM5; HTR2A; DRD4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.692E-05 | 2.391E-04 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.082E-04 | 4.656E-04 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; PTPRF |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.703E-04 | 6.704E-04 | GSK3B; CASP7; AKT1; PIK3R1; PPARA; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.029E-04 | 4.569E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.097E-04 | 7.462E-04 | ABCC1; PIM1; CYP1B1; TP53; MMP9; MET; NFKB1; CDC25B |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 2.335E-04 | 7.856E-04 | PLA2G1B; KDR; AKT1; PIK3R1; MET; NFKB1; IGF1R |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.907E-04 | 7.054E-04 | CDK1; AKT1; PIK3R1; CDC25B; IGF1R |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.907E-04 | 7.054E-04 | CAMK2B; SRC; ALOX12; PIK3R1; HTR2A |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.196E-04 | 7.601E-04 | MMP2; PIM1; AKT1; PIK3R1; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.999E-04 | 7.253E-04 | SRC; MMP2; AKT1; PIK3R1; MMP9 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 4.380E-04 | 1.325E-03 | CHRM2; CAMK2B; CHRM3; CHRM1; CHRM5; HTR2A |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 5.050E-04 | 1.437E-03 | POLB; GSK3B; TERT; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 4.511E-04 | 1.325E-03 | ALOX5; AKT1; PIK3R1; NFKB1; TLR2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 8.664E-04 | 2.196E-03 | POLB; SRC; CDK1; PIK3R1; TP53; NFKB1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.006E-03 | 2.515E-03 | SRC; KDR; AKT1; PIK3R1; MET; IGF1R |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 6.771E-04 | 1.764E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.674E-03 | 4.075E-03 | PIM1; AKT1; STAT6; PIK3R1; PTPN2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.043E-03 | 2.573E-03 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.783E-04 | 6.873E-04 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.189E-03 | 5.145E-03 | BACE1; GSK3B; CASP7; MAPT; HSD17B10 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.613E-03 | 5.837E-03 | GSK3B; CASP1; AKT1; PIK3R1; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.812E-03 | 6.192E-03 | CAMK2B; SRC; AKT1; NFKB1; TLR2 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 3.317E-03 | 7.220E-03 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.327E-05 | 3.080E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.119E-03 | 5.090E-03 | PIK3R1; NFKB1; PTK2; TLR2 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 2.197E-03 | 5.145E-03 | CAMK2B; AKT1; PYGL; PPARA |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 4.480E-04 | 1.325E-03 | AKT1; PIK3R1; MET; HIF1A |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.480E-04 | 1.325E-03 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.444E-03 | 5.581E-03 | AKT1; PIK3R1; NFKB1; TLR2 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.525E-04 | 1.124E-03 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.619E-03 | 5.837E-03 | AKT1; PIK3R1; NFKB1; TLR2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.444E-03 | 5.581E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.380E-04 | 7.861E-04 | ALK; AKT1; PIK3R1; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 6.573E-04 | 1.737E-03 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 4.226E-04 | 1.325E-03 | RORC; STAT6; NFKB1; TLR2 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 6.573E-04 | 1.737E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.248E-02 | 2.285E-02 | AKT1; MAPT; TP53; NFKB1; CDC25B |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.327E-02 | 2.360E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 7.384E-03 | 1.438E-02 | GSK3B; AKT1; PIK3R1; IGF1R |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 5.725E-03 | 1.151E-02 | AKT1; PPARG; PIK3R1; NFKB1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 4.593E-03 | 9.441E-03 | AKT1; PPARG; PIK3R1; IGF1R |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.219E-04 | 7.601E-04 | CASP7; CASP1; NFKB1; TLR2 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 4.593E-03 | 9.441E-03 | GSK3B; CDK1; TP53; CDC25B |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 3.851E-03 | 8.188E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 5.021E-04 | 1.437E-03 | CXCR1; SRC; MET; NFKB1 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 8.438E-04 | 2.168E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.308E-04 | 1.488E-03 | CYP2C8; MAOA; CYP1A2; CYP3A4 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.846E-02 | 4.674E-02 | SRC; AKT1; PIK3R1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.916E-04 | 1.610E-03 | CA2; NR1H4; CYP3A4; ABCG2 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 2.906E-02 | 4.674E-02 | CAMK2B; CDK1; IGF1R |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 3.152E-02 | 4.984E-02 | GSK3B; MET; PTK2 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.741E-02 | 3.011E-02 | AKT1; PIK3R1; HIF1A |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.319E-02 | 2.360E-02 | CAMK2B; SRC; MMP2 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.522E-02 | 2.681E-02 | CHRM3; CA2; PLA2G1B |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.206E-02 | 2.230E-02 | SRC; CDK1; HTR2A |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.133E-02 | 2.117E-02 | CASP1; PKN1; NFKB1 |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 7.519E-03 | 1.449E-02 | CAMK2B; CHRM3; CA2 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 6.448E-03 | 1.283E-02 | AKT1; PPARA; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 7.802E-03 | 1.488E-02 | CASP7; CASP1; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 4.191E-03 | 8.811E-03 | AKT1; PIK3R1; HIF1A |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 5.024E-03 | 1.021E-02 | AKT1; PIK3R1; IGF1R |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 3.448E-03 | 7.418E-03 | FABP4; AKT1; PIK3R1 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 3.102E-02 | 4.948E-02 | CASP1; TP53 |
| hsa05144 | Malaria_Homo sapiens_hsa05144 | 2.881E-02 | 4.674E-02 | MET; TLR2 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.881E-02 | 4.674E-02 | MAOA; NFKB1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.460E-02 | 4.137E-02 | AKT1; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.563E-02 | 4.271E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.358E-02 | 4.003E-02 | ABCC1; ABCG2 |
| hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 2.066E-02 | 3.539E-02 | FABP2; PLA2G1B |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.591E-04 | 1.544E-03 | AKR1B10; GAA; AKR1B1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.067E-02 | 2.014E-02 | PPARG; TP53 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.289E-02 | 2.339E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.615E-02 | 2.819E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 6.788E-03 | 1.336E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.859E-04 | 9.278E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R; TERT |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH |
| NA: NA | Functional bowel syndrome | NA | CHRM1 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | CHRM3; ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2A |
| N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3; CHRM4 |
| J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; GPBAR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Urinary retention | R33 | CHRM4 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; TERT; TLR2; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CHRM3; MMP13; ACHE; IGF1R; CDK1; FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; CHRM1; CHRM1; CHRM4; ACHE; CHRM2 |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | CHRM4; HTR2A |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| NA: NA | Peptic ulcer disease | NA | CHRM4 |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5 |
| NA: NA | Suprapubic pain | NA | CHRM4 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; CHRM4; HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| NA: NA | Moderate and severe psychomotor agitation | NA | CHRM4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; HTR2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; IGF1R; IGF1R; KDR |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; PPARG; PPARD; PPARD |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; HSD11B1; HSD11B1; PTPN1; GSK3B; HTR2A; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | CHRM5; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Mydriasis diagnosis | H57.0 | CHRM4 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Organophosphate poisoning | T60.0 | CHRM4 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; CYP19A1; FLT3; FLT3; IGF1R; TERT; CDK1; KDR; KDR; KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | CHRM4 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM4; CHRM2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1; FAAH |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA9; AKT1; MET; CSNK2A1; FLT3; FLT3; MMP2; ACHE; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MMP9; NFKB1; PIM1; CDC25B; TLR2; TP53; CA1; KDR |
| J00-J99: Diseases of the respiratory system | Bronchodilator | J45 | CHRM4 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | CHRM4; CHRM4 |
| NA: NA | Gastritis | NA | CHRM4 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; AKT1; MET; CHRM4; FLT3; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MMP9; TLR2; TP53; KDR; KDR; KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | CHRM4; CHRM4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| NA: NA | Excessive sweating | NA | CHRM1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; TERT; KDR; KDR; KDR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; PTPN1; PTPN1; NFKB1; PPARG; PPARG; GPBAR1; PPARD |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; KDR; CHRM2 |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CHRM1; CHRM3; CHRM4; ACHE; ADORA3; HTR2A; CA1; CA1 |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR2A |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1 |
| H00-H59: Diseases of the eye and adnexa | Acquired nystagmus | H55 | CHRM4 |
| NA: NA | Abdominal stomach pain | NA | CHRM1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM1; CHRM1; CHRM1; CHRM5; HTR2A; HTR2A; DRD4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | CHRM4 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; TERT |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TERT; TP53; TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; CHRM2 |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53; KDR; KDR |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ALOX5; CASP1; MMP3; CAMK2B |
| NA: NA | Schizoaffective disorders | NA | CHRM1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dystonia | NA | CHRM1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; CHRM1; CHRM3; CHRM4; CHRM5; ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; TERT; KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nocturia | R35 | CHRM4 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRM1; CHRM5; NPSR1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRM1; CHRM5; MAPT; ACHE |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| NA: NA | Spasms | NA | CHRM3 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| NA: NA | Vomiting | NA | CHRM4 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; AKT1; HIF1A |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM4; CHRM5 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; HTR2A; PPARD |
| NA: NA | Addiction | NA | HTR2A; CHRM2 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | CHRM5; PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; CHRM1; CHRM3; CHRM4; MAPT; ACHE; ACHE; ACHE; GSK3B; PPARG; PPARG; CHRM2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CHRM4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| H00-H59: Diseases of the eye and adnexa | Produce mydriasis and cycloplegia for diagnostic purposes | H57.04 | CHRM4 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; TERT; TLR2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM1; CHRM4; CHRM4; CHRM5 |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM4; CHRM4; CHRM4; CHRM2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Dysuria | NA | CHRM4 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; FAAH |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; CHRM3; CHRM5; CHRM2 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Urgency | NA | CHRM4 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; CAMK2B; ACHE; FAAH; HTR2A; CYP3A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; HTR2A |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3 |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; CHRM1 |
| NA: NA | Uveitis | NA | CHRM4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; TLR2; KDR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | CHRM4 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; CHRM2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; ALOX5; PPARD |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | CHRM4; ACHE |